Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition
DARE-HRT1 is a potential treatment of menopause-related symptoms DARE-FRT1 is a potential pregnancy maintenance therapy SAN DIEGO , July 22, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will be presenting two posters at
View HTML
Toggle Summary Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model
DARE-VVA1 is a proprietary formulation of tamoxifen for vaginal administration as a potential treatment for VVA in patients with hormone receptor-positive breast cancer SAN DIEGO , July 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today
View HTML
Toggle Summary Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
SAN DIEGO , July 15, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, announced today that William H. Rastetter , Ph.D., a current member of its Board of Directors, was appointed Chairman of its Board of Directors effective July 11, 2019 .
View HTML
Toggle Summary Daré Bioscience Completes Recruitment in Pre-Pivotal Trial Of Monthly Woman-Controlled, Hormone-Free Contraceptive Candidate, Ovaprene®
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive SAN DIEGO, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced completion of patient recruitment in its
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
SAN DIEGO , June 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of
View HTML
Toggle Summary Daré Bioscience to Present at the 2019 BIO International Convention
SAN DIEGO , May 29, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson , President and Chief Executive Officer, will present at the 2019 BIO International Convention on Tuesday, June 4, 2019 , starting at 11:15
View HTML
Toggle Summary Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update
SAN DIEGO , May 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2019 and provided a Company update. “The first quarter was an active one for Daré and positioned us well
View HTML
Toggle Summary Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research
SAN DIEGO, May 8, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep” was published online in the journal Drug Delivery and
View HTML
Toggle Summary Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast
SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2019, to review the Company's financial results for the quarter
View HTML
Toggle Summary Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development
SAN DIEGO , April 15, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal ring
View HTML